SCHEMBL641183

SCHEMBL641183

O=C(Nc1ccccc1Oc1ccc(Cl)cc1Cl)C1CCNCC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.53
PKM P14618 1/20 0.53
KMT2A Q03164 3/20 0.49
MEN1 O00255 2/20 0.49
SMN1; SMN2 Q16637 1/20 0.46
SIRT2 Q8IXJ6 1/20 0.46
CHRM1 P11229 1/20 0.45
HTR1A P08908 1/20 0.45
SLC6A2 P23975 1/20 0.45
SLC6A4 P31645 1/20 0.45
KDM4E B2RXH2 1/20 0.44
ROCK2 O75116 1/20 0.44
CXCR2 P25025 1/20 0.44
MAPT P10636 2/20 0.44
PLA2G1B P04054 1/20 0.44
ATG4B Q9Y4P1 1/20 0.44
ALDH1A1 P00352 2/20 0.43
ALOX12 P18054 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
GPR55 Q9Y2T6 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL641983 0.86 GAA (0.66) GAAPKMKMT2AMEN1SMN1; SMN2
SCHEMBL5073382 0.84 GAA (0.52) GAAPKMKMT2AMEN1SMN1; SMN2
SCHEMBL640994 0.84 ACHE (0.51) GAAPKMKMT2AMEN1SMN1; SMN2
SCHEMBL642234 0.83 GAA (0.62) GAAPKMKMT2AMEN1SMN1; SMN2
SCHEMBL642341 0.82 ACHE (0.66) KMT2AMEN1SMN1; SMN2ALDH1A1
SCHEMBL642893 0.82 ALDH1A1 (0.62) GAAKMT2AMEN1SMN1; SMN2MAPT
SCHEMBL9965441 0.82 SMN1; SMN2 (0.48) GAAPKMKMT2AMEN1SMN1; SMN2
SCHEMBL9965439 0.81 KMT2A (0.53) GAAPKMKMT2AMEN1SMN1; SMN2
SCHEMBL9965398 0.81 SMN1; SMN2 (0.50) GAAPKMKMT2AMEN1SMN1; SMN2
SCHEMBL640909 0.81 SLC6A4 (0.48) CHRM1HTR1ASLC6A2SLC6A4MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11571433-B2 Methods for treating memory impairment and cognitive dysfunction CARMEL HAIFA UNIVERSITY ECONOMIC CORPORATION LTD. (IL) 2023-02-07 US claimed
CN-114404425-A Inhibitor of phosphodiesterase and application thereof 南京中医药大学 2022-04-29 CN claimed
CN-114395011-A Preparation method of natural bufogenin lactone compounds 上海中医药大学 2022-04-26 CN claimed
US-20210085693-A1 METHODS FOR TREATING MEMORY IMPAIRMENT AND COGNITIVE DYSFUNCTION CARMEL HAIFA UNIVERSITY ECONOMIC CORPORATION LTD. (IL) 2021-03-25 US claimed
EP-3755340-A1 METHODS FOR TREATING MEMORY IMPAIRMENT AND COGNITIVE DYSFUNCTION Carmel-Haifa University Economic Corporation Ltd. (IL) 2020-12-30 EP claimed
WO-2019162945-A1 METHODS FOR TREATING MEMORY IMPAIRMENT AND COGNITIVE DYSFUNCTION CARMEL HAIFA UNIVERSITY ECONOMIC CORPORATION LTD. (IL) 2019-08-29 WO claimed
CN-104034834-B The detection method of bufanolide dienes ingredients fingerprint and application thereof in a kind of dried venom of toads medicinal material HEHUANG PHARMACEUTICAL CO., LTD., SHANGHAI (CN) 2015-08-19 CN claimed
CN-104034834-A Method for detecting fingerprints of toad bufanolide diene compositions in toad medicinal materials and application of method SHANGHAI HUTCHISON PHARMACEUTICALS CO LTD 2014-09-10 CN claimed
CN-103599112-A Application of bufanolide diene compound in preparation of medicines for treating sepsis immune paralysis NANJING UNIVERSITY OF TECHNOLOGY 2014-02-26 CN claimed
CN-1985851-B Lipoid microsphere injection containing toad cake extract and its preparing method SHENYANG YAODA MEDICINE DEV CO LTD 2012-01-25 CN claimed
CN-1985851-A Lipoid microsphere injection containing toad cake extract and its preparing method SHENYANG YAODA MEDICINE DEV CO (CN) 2007-06-27 CN claimed
WO-2006120472-A2 NOVEL BETA-STEROID COMPOUNDS GUY'S AND ST THOMAS'NHS FOUNDATION TRUST (GB) 2006-11-16 WO claimed
EP-4619039-A1 METHODS AND COMPOSITIONS INCLUDING CONJUGATED DNAZYMES 1E Therapeutics, Ltd. (IL) 2025-09-24 EP disclosed
WO-2024105654-A1 METHODS AND COMPOSITIONS INCLUDING CONJUGATED DNAZYMES 1E THERAPEUTICS, LTD. (IL) 2024-05-23 WO disclosed
US-20230265424-A1 METHODS OF TREATING AND PREVENTING BACTERIAL INFECTIONS 1E THERAPEUTICS LTD. (IL) 2023-08-24 US disclosed
EP-3394080-B1 LIPID-LINKED PRODRUGS UNIV BRITISH COLUMBIA (CA) 2023-06-07 EP disclosed
US-5932613-A PINE ROOT FUNGAL METABOLITE OR ANALOG MILLENNIUM PHARMACEUTICALS, INC. (US) 1999-08-03 US disclosed
US-5917084-A PINE ROOT (DEUTERO MYCETES) FUNGAL METABOLITE, NATURALLY OCCURRING TERPENOID COMPOUNDS MILLENNIUM PHARMACEUTICALS, INC. (US) 1999-06-29 US disclosed
WO-1998000091-A2 ANTIFUNGAL AGENTS MILLENNIUM PHARMACEUTICALS, INC. (US) 1998-01-08 WO disclosed
WO-1998000121-A1 ANTICANCER AGENTS MILLENNIUM PHARMACEUTICALS, INC. (US) 1998-01-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230265424-A1 METHODS OF TREATING AND PREVENTING BACTERIAL INFECTIONS DNASE1, UNG, DNASE1L3 GAA 82/4885PKM 3265/4885KMT2A 1927/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.